Update on reintroduction of epoetin in a patient with pure red call aplasia.
Neil
N
Campbell
Sarietha
S
Krishnakumar
Ante
A
Matijevic
Mike
M
Almond
D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy; D016572:Cyclosporine / Q000627:therapeutic use; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects*; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000188:drug therapy; D008297:Male; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced*
D006397:Hematinics; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa; D016572:Cyclosporine